ARCHIVES

Six-Year Follow Up Of Phase III Sprycel Trial Demonstrates 71 Percent Overall Survival

This article is from The Cancer Letter archive.

Vol. 35 No. 7 | July 27, 2012

Download PDF Visit The Full Archive

Related Articles

DCT’s Experimental Therapeutic Program Outlined to Board

May 2, 1975

In Brief: Pagano to Retire As Lineberger Director; Nursing Society Elects Yarbro As President

September 20, 1996

FDA Committee Okays Leuprolide NDA, But Recommends Against Mitoxantrne, Epirubicin

April 5, 1985

DCT Advisors Reject MRS Concept, Approve RDOG Expansion

November 30, 1990

HPV Can Affect Response To Radiation Therapies

September 28, 2012

In Brief: Thomas, Murray share Nobel Prize for Medicine; Wynder To Present Carese Memorial Lecture

October 12, 1990